These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 8529131

  • 1. Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate.
    Huang Y, Snyder R, Kligshteyn M, Wickstrom E.
    Mol Med; 1995 Sep; 1(6):647-58. PubMed ID: 8529131
    [Abstract] [Full Text] [Related]

  • 2. Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates.
    Wickstrom E, Bacon TA, Wickstrom EL.
    Cancer Res; 1992 Dec 15; 52(24):6741-5. PubMed ID: 1458461
    [Abstract] [Full Text] [Related]

  • 3. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model.
    Smith JB, Wickstrom E.
    J Natl Cancer Inst; 1998 Aug 05; 90(15):1146-54. PubMed ID: 9701364
    [Abstract] [Full Text] [Related]

  • 4. Antisense oligodeoxynucleoside methylphosphonate inhibition of mouse c-myc p65 protein expression in E mu-c-myc transgenic mice.
    Wickstrom E, Bacon TA, Wickstrom EL, Werking CM, Palmiter RD, Brinster RL, Sandgren EP.
    Nucleic Acids Symp Ser; 1991 Aug 05; (24):151-4. PubMed ID: 1841270
    [Abstract] [Full Text] [Related]

  • 5. Antisense c-myc inhibition of lymphoma growth.
    Wickstrom E.
    Antisense Nucleic Acid Drug Dev; 1997 Jun 05; 7(3):225-8. PubMed ID: 9212915
    [No Abstract] [Full Text] [Related]

  • 6. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
    Polack A, Feederle R, Klobeck G, Hörtnagel K.
    EMBO J; 1993 Oct 05; 12(10):3913-20. PubMed ID: 8404859
    [Abstract] [Full Text] [Related]

  • 7. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT, Neckers LM, Schneller HE, Woodruff LS, Magrath IT.
    Cancer Res; 1993 Jan 01; 53(1):127-32. PubMed ID: 8416737
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G, Carpaneto EM, Ponzanelli A, Ulivi M, Millo E, Scarfì S, Roncella S, Benatti U, Boffa LC, Ferrarini M.
    Cancer Res; 2003 Oct 01; 63(19):6144-8. PubMed ID: 14559793
    [Abstract] [Full Text] [Related]

  • 9. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE, Lieberman R, Sandlund J, Kiwanuka J, Novikovs L, Kirsch I, Hollis G, Magrath IT.
    Cancer Res; 1989 Jun 15; 49(12):3235-41. PubMed ID: 2497974
    [Abstract] [Full Text] [Related]

  • 10. Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis.
    Pacilli A, Calienni M, Margarucci S, D'Apolito M, Petillo O, Rocchi L, Pasquinelli G, Nicolai R, Koverech A, Calvani M, Peluso G, Montanaro L.
    J Natl Cancer Inst; 2013 Apr 03; 105(7):489-98. PubMed ID: 23486551
    [Abstract] [Full Text] [Related]

  • 11. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA, Chang L, Buzby JS, Suen Y, Cairo MS.
    Leukemia; 1996 Dec 03; 10(12):1980-9. PubMed ID: 8946941
    [Abstract] [Full Text] [Related]

  • 12. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma.
    Williams SA, Gillan ER, Knoppel E, Buzby JS, Suen Y, Cairo MS.
    Ann Oncol; 1997 Dec 03; 8 Suppl 1():25-30. PubMed ID: 9187425
    [Abstract] [Full Text] [Related]

  • 13. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
    Polack A, Strobl L, Feederle R, Schweizer M, Koch E, Eick D, Wiegand H, Bornkamm GW.
    Oncogene; 1991 Nov 03; 6(11):2033-40. PubMed ID: 1945409
    [Abstract] [Full Text] [Related]

  • 14. Course of c-myc mRNA expression in the regenerating mouse testis determined by competitive reverse transcriptase polymerase chain reaction.
    Amendola R.
    DNA Cell Biol; 1994 Nov 03; 13(11):1099-107. PubMed ID: 7535536
    [Abstract] [Full Text] [Related]

  • 15. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
    Palomo C, Zou X, Nicholson IC, Bützler C, Brüggemann M.
    Cancer Res; 1999 Nov 01; 59(21):5625-8. PubMed ID: 10554044
    [Abstract] [Full Text] [Related]

  • 16. Id2 is dispensable for myc-induced lymphomagenesis.
    Nilsson JA, Nilsson LM, Keller U, Yokota Y, Boyd K, Cleveland JL.
    Cancer Res; 2004 Oct 15; 64(20):7296-301. PubMed ID: 15492249
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc.
    Boffa LC, Cutrona G, Cilli M, Matis S, Damonte G, Mariani MR, Millo E, Moroni M, Roncella S, Fedeli F, Ferrarini M.
    Cancer Gene Ther; 2007 Feb 15; 14(2):220-6. PubMed ID: 17053816
    [Abstract] [Full Text] [Related]

  • 18. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations.
    Müller JR, Janz S, Potter M.
    Cancer Res; 1995 Nov 01; 55(21):5012-8. PubMed ID: 7585544
    [Abstract] [Full Text] [Related]

  • 19. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
    Strobl LJ, Kohlhuber F, Mautner J, Polack A, Eick D.
    Oncogene; 1993 Jun 01; 8(6):1437-47. PubMed ID: 8502472
    [Abstract] [Full Text] [Related]

  • 20. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
    Jochner N, Eick D, Zimber-Strobl U, Pawlita M, Bornkamm GW, Kempkes B.
    EMBO J; 1996 Jan 15; 15(2):375-82. PubMed ID: 8617212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.